NanoHive Medical is a pioneer and leading innovator in 3D printed spinal interbody fusion implants and instrumentation. The company’s proprietary, biomimetic Soft Titanium™ technology distinguishes their products in the $2.2B spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provides spine surgeons and their patients with the ideal features that lead to consistently strong fusion constructs and efficacious clinical experiences.

ChitogenX is a clinical stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries. Ortho-R, the company's lead Chitosan-based biopolymer and Platelet-Rich Plasma (PRP) hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments

Renovos Biologics is a new regenerative medicine company capitalizing on the decades of world-class stem cell and orthopaedic research from the University of Southampton. Renovos is developing next-generation regenerative medicine solutions, based on a synthetic nanoclay gel technology platform, Renovite.

BONESUPPORT™ is a global leader in the orthobiologics markets dedicated to the development and commercialization of highly innovative injectable biomaterials and drug combination therapies that provide solutions for treatment of bone remodeling, infection, and tumor applications.

ProteoThera, Inc. is an early stage biotechnology company that is advancing drug targeting technology. The Company raised $5M in a Series A to fund concept development milestones. The Company's transformative platform technology, a proprietary tissue matrix-binding (MB) peptide technology, is being developed to allow for the local delivery of FDA approved and validated therapeutics for the treatment of articular joint pain and tissue regeneration.

In May, 2011, Histogenics announced the acquisition of Prochon BioTech, in a stock-for-stock exchange. Subsequently, the Company raised $49M in Series C funding round to finance the clinical milestones. Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. The company’s flagship products focus on the treatment of active patients suffering from articular… Show more In May, 2011, Histogenics announced the acquisition of Prochon BioTech, in a stock-for-stock exchange. Subsequently, the Company raised $49M in Series C funding round to finance the clinical milestones. Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. The company’s flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. Histogenics is located in Waltham, Massachusetts. Show less

Led company in a stock-for-stock transaction merger with Histogenics Corporation. The Company raised $12M in a Series B round to finance clinical milestones. Prochon BioTech was a cell therapy biologics company with internal development focused on articular cartilage regeneration. Prochon's flagship product, BioCart had completed Phase II FDA clinical study enrollment and was commercial in Israel. ProChon was located in the Weizman Science Park, Nes Ziona, Israel with the senior management… Show more Led company in a stock-for-stock transaction merger with Histogenics Corporation. The Company raised $12M in a Series B round to finance clinical milestones. Prochon BioTech was a cell therapy biologics company with internal development focused on articular cartilage regeneration. Prochon's flagship product, BioCart had completed Phase II FDA clinical study enrollment and was commercial in Israel. ProChon was located in the Weizman Science Park, Nes Ziona, Israel with the senior management team located in Woburn, Massachusetts. Show less

Leading biomaterials startup company with PEG hydrogel technology for neurosurgical and other surgical sealant applications. Company acquired by Covidien Healthcare for $235M.

Sales, Sales Management, Product & Marketing Management, Strategic Partner Alliance Management escalating positions of management for spinal instrumentation, orthobiologic and biomaterial technologies.